The present invention provides radioactive dermatological patch designed to topically treat cutaneous skin lesions in patient tissue. The radioactive dermatological patch includes a layer of a radionuclide with a nonreactive binding agent to form a treatment wafer. The treatment wafer is then placed within the radioactive dermatological patch. The radioactive dermatological patch includes a high Z distal shielding layer placed adjacent the side of treatment wafer away from the patient tissue. The distal shielding layer attenuating the energy of the radionuclide from the environment external to the patient. The patch further includes a high Z proximal patient shielding layer placed between the patient tissue and treatment wafer.

An apparatus comprising a radiation source, coincident positron omission detectors configured to detect coincident positron annihilation emissions originating within a coordinate system, and a controller coupled to the radiation source and the coincident positron emission detectors, the controller configured to identify coincident positron annihilation emission paths intersecting one or more volumes in the coordinate system and align the radiation source along an identified coincident positron annihilation emission path.

Presented systems and methods facilitate efficient and effective generation and delivery of radiation. In one embodiment, a radiation generation component includes a high intensity target that produces Bremsstrahlung radiation in response to impacts by charged particles, wherein the high intensity target is configured with operating limitations based primarily on catastrophic failure mechanisms rather than fatigue failure mechanisms. The high intensity target is configured to be compatible with a loading system of a radiation generation system. The high intensity target can have a catastrophic failure strain percentage in the range of 0.5 to 4.0 percent. The catastrophic failure mechanisms can include at least one selected from the group comprising ultimate tensile strength, fracture strain, and melting point. The high intensity target can have a product life in a low cycle fatigue regime range. The high intensity target can comprise a material with a melting temperature in the range of 800 C to 3,700 C. The high intensity target can be configured to load in an accelerator enclosure. The high intensity target can include an identification feature. Th e Bremsstrahlung radiation can correspond to average dose rates greater than 1.0 greys per second (Gy/s).

A patient-positioning device and a medical workstation including the patient-positioning device. The patient-positioning device includes a patient couch and a robot arm which is provided for moving the patient couch and which comprises several links arranged one after another and mounted rotatably with respect to axes. The robot arm includes, as links, a start link, a first link, a second link, a third link, a fourth link, a fifth link and a sixth link. The robot arm comprises a patient couch or a fastening device on which the patient couch is fastened.

A pharmaceutical composition for modifying a target structure, which includes at least one agent selected from the group consisting of energy modulation agents, plasmonics-active agents and combinations thereof; the energy modulation agents, when present, including one or more light emitters capable of emitting at least two different wavelengths of light, each wavelength of light associated with a different biological response, and the at least two different wavelengths capable of activating different biological responses; and a pharmaceutically acceptable carrier.

Systems and methods for determining a target multi-source model of a radiation source corresponding to an energy spectrum is provided. The systems may obtain an initial multi-source model of the radiation source, which includes an initial phase space file that includes information of a plurality of simulated particles of a plurality of energy levels. The systems may estimate, based on the initial phase space file, a plurality of component PDD curves corresponding to the plurality of energy levels. The systems may obtain a measured PDD curve corresponding to radiation of the energy spectrum. For each energy level, the systems may determine, based on the plurality of component PDD curves and the measured PDD curve, a weight for the each energy level. The systems may further determine the target multi-source model of the radiation source based at least in part on the initial multi-source model and the weights.

A computer-based method of optimizing a radiotherapy treatment plan for a patient is proposed, wherein a treatment plan to be provided by one radiation set is optimized taking into account a previously delivered dose delivered by a different radiation set. One of the radiation sets is external beam radiotherapy and the other is brachytherapy.

A balloon applicator for an intraoperative radiation therapy system includes an x-ray beam shaping component for emitting x-rays in a plurality of possible directions in three dimensions. The balloon applicator includes connecting structure for connecting to the intraoperative radiation therapy system and an inflatable balloon contactor having an outer surface. The balloon applicator has a beam hardening system including a beam hardening compound disposed between the x-ray beam shaping component and the outer surface of the balloon. The beam hardening system is capable of hardening the beam in beam directions in three dimensions. An intraoperative radiation therapy system and a method for conducting intraoperative radiation therapy are also disclosed.

An example computer-implemented method for tuning a beam spot in a radiation therapy system based on radiation field measurements has been disclosed. The example method includes configuring an electron beam to generate a first beam spot on an electron-beam target of the radiation therapy system, determining a value for one or more radiation field quality metrics for a first radiation beam that originates from the first beam spot, and based on the value, determining whether the first radiation beam is outside a specified quality range.

Conventional single fraction 20-Gy broadbeam photonbeam or protonbeam chemo-radiosurgery does not sterilize EMT-MET cancer stem cell radiodurans but single fraction 100 to 10,000 Gy microbeam radiosurgery sterilizes them. Device and methods for microbeam chemo-radiosurgery including 250 MeV wakefield electronbeam is disclosed.

Surgery, chemotherapy and broadbeam and microbeam radiosurgery releases billions of abscopal metastasis causing, tumor specific plasma soluble proteins, cell membranes, apoptotic bodies, DNA and RNAs, exosomes like telomere-telomerase, ATM-ATM kinase and others. They and adaptive resistance to chemo-radiosurgery, paraneoplastic and non-paraneoplastic diseases causing immune complexes are removed by pulse flow combined continuous flow ultracentrifugation apheresis and immune affinity chromatography. Chemotherapy and high dose radiation exposed tumor cells and their exosomes are made sensitive to telomerase inhibiting and apoptosis inducing and least toxic epigallocatechin and to heparin bound receptors. They convert triple negative breast tumors into receptor positive tumors which open new avenues for treating most aggressive breast cancers.